Header Logo

Reina Haque

Concepts (318)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
31
2022
1023
5.280
Why?
Prostatic Neoplasms
13
2022
299
2.930
Why?
Tamoxifen
9
2016
60
2.720
Why?
Cancer Survivors
4
2022
88
2.410
Why?
Neoplasm Recurrence, Local
14
2024
249
2.170
Why?
Aromatase Inhibitors
6
2016
34
2.160
Why?
Survivors
10
2022
157
1.970
Why?
Antineoplastic Agents, Hormonal
7
2017
65
1.770
Why?
Aged
54
2024
6258
1.510
Why?
Humans
78
2024
18058
1.500
Why?
Androgen Antagonists
5
2017
17
1.450
Why?
Neoplasms
3
2023
464
1.450
Why?
Middle Aged
55
2024
8073
1.360
Why?
Cardiovascular Diseases
6
2017
613
1.210
Why?
Female
46
2024
12838
1.130
Why?
Depressive Disorder
2
2022
233
1.080
Why?
Proportional Hazards Models
13
2021
745
1.070
Why?
California
21
2023
2327
1.070
Why?
Neoplasms, Second Primary
2
2016
31
0.970
Why?
CA-125 Antigen
2
2020
6
0.920
Why?
Membrane Proteins
2
2020
40
0.900
Why?
Health Maintenance Organizations
4
2017
481
0.880
Why?
Ovarian Neoplasms
2
2020
48
0.870
Why?
Adult
31
2022
7696
0.840
Why?
Aged, 80 and over
20
2021
1956
0.840
Why?
Neoplasm Staging
13
2016
330
0.840
Why?
Paroxetine
2
2015
23
0.800
Why?
Male
38
2024
10173
0.760
Why?
Risk Factors
19
2021
3394
0.750
Why?
Retrospective Studies
13
2023
2498
0.730
Why?
Health Services Accessibility
1
2023
316
0.720
Why?
Depression
3
2022
512
0.720
Why?
Cohort Studies
20
2022
2631
0.700
Why?
Obesity
4
2021
839
0.680
Why?
Insurance, Health
1
2021
221
0.670
Why?
Healthcare Disparities
1
2021
205
0.650
Why?
Endometrial Neoplasms
2
2015
39
0.640
Why?
Patient Compliance
3
2020
303
0.620
Why?
Arrhythmias, Cardiac
1
2017
31
0.600
Why?
Protein Kinase Inhibitors
1
2017
2
0.590
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2017
2
0.590
Why?
Sigmoidoscopy
2
2007
67
0.540
Why?
Prognosis
11
2022
619
0.540
Why?
Algorithms
4
2020
235
0.540
Why?
Antidepressive Agents, Second-Generation
1
2015
28
0.530
Why?
Pathology Department, Hospital
1
2015
3
0.520
Why?
Lymphoma, Large B-Cell, Diffuse
4
2017
14
0.510
Why?
Diphosphonates
1
2016
64
0.510
Why?
Overweight
2
2021
272
0.500
Why?
Carcinoma, Intraductal, Noninfiltrating
5
2015
42
0.500
Why?
Medication Adherence
2
2017
255
0.500
Why?
Radiotherapy, Adjuvant
4
2016
18
0.490
Why?
Biomarkers, Tumor
4
2020
144
0.460
Why?
Urinary Bladder Neoplasms
2
2024
60
0.430
Why?
Arsenic
4
2007
5
0.430
Why?
Research Design
1
2015
393
0.430
Why?
Antidepressive Agents
2
2022
162
0.420
Why?
Multivariate Analysis
4
2021
595
0.420
Why?
Social Class
3
2023
125
0.410
Why?
Inflammation
1
2012
61
0.410
Why?
Heart Failure
1
2017
391
0.410
Why?
Neoplasm Grading
4
2017
48
0.410
Why?
Follow-Up Studies
11
2024
1255
0.410
Why?
Sleep Wake Disorders
1
2012
40
0.410
Why?
Mass Screening
2
2009
678
0.400
Why?
Prostate-Specific Antigen
3
2016
77
0.400
Why?
Prospective Studies
11
2024
1294
0.390
Why?
Risk Reduction Behavior
1
2012
114
0.390
Why?
Registries
7
2021
486
0.380
Why?
Continental Population Groups
2
2009
317
0.380
Why?
Carcinoma, Ductal
1
2010
5
0.370
Why?
Body Mass Index
3
2013
961
0.360
Why?
Socioeconomic Factors
3
2023
667
0.360
Why?
Preventive Health Services
1
2012
164
0.360
Why?
Cross-Sectional Studies
10
2012
1309
0.350
Why?
Risk
6
2020
552
0.350
Why?
Electronic Health Records
1
2015
734
0.340
Why?
Comorbidity
4
2023
618
0.340
Why?
Prostatectomy
5
2016
79
0.340
Why?
Case-Control Studies
13
2015
1164
0.340
Why?
Prostate
2
2022
29
0.330
Why?
Incidence
9
2015
1297
0.320
Why?
Water Supply
3
2007
8
0.310
Why?
Gonadotropin-Releasing Hormone
3
2017
11
0.310
Why?
Managed Care Programs
1
2010
356
0.310
Why?
Environmental Exposure
4
2007
108
0.310
Why?
Insurance Carriers
1
2007
6
0.300
Why?
Organizations, Nonprofit
1
2007
12
0.300
Why?
Practice Patterns, Physicians'
1
2010
351
0.290
Why?
Keratosis
2
2004
2
0.290
Why?
Salvage Therapy
2
2016
18
0.280
Why?
Treatment Outcome
8
2024
1259
0.270
Why?
Colorectal Neoplasms
3
2010
643
0.270
Why?
Longitudinal Studies
3
2022
705
0.260
Why?
Young Adult
6
2022
2479
0.260
Why?
Survival Rate
4
2014
266
0.260
Why?
HIV Infections
3
2017
682
0.260
Why?
Receptor, ErbB-2
2
2016
47
0.250
Why?
Ethnic Groups
2
2021
504
0.250
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
3
2015
177
0.250
Why?
Sensitivity and Specificity
4
2020
318
0.250
Why?
Odds Ratio
6
2017
692
0.250
Why?
Mitomycin
1
2024
4
0.240
Why?
Isothiocyanates
1
2024
8
0.240
Why?
BCG Vaccine
1
2024
6
0.240
Why?
Logistic Models
7
2013
953
0.230
Why?
Ultrasonography
2
2020
36
0.230
Why?
Hyperpigmentation
1
2003
1
0.230
Why?
Early Detection of Cancer
3
2020
510
0.220
Why?
Colonoscopy
1
2005
265
0.210
Why?
Lower Urinary Tract Symptoms
2
2013
13
0.210
Why?
Electronic Nicotine Delivery Systems
1
2022
32
0.210
Why?
Breast
1
2022
85
0.210
Why?
Hallucinogens
1
2022
23
0.210
Why?
Hip Fractures
2
2015
70
0.200
Why?
Arsenic Poisoning
3
2007
3
0.200
Why?
United States
7
2015
4119
0.200
Why?
Feasibility Studies
2
2020
116
0.200
Why?
Sleep
1
2021
56
0.200
Why?
Chemotherapy, Adjuvant
4
2015
70
0.190
Why?
Depressive Disorder, Major
1
2022
128
0.190
Why?
Mammography
3
2012
173
0.190
Why?
Cannabis
1
2022
73
0.190
Why?
Erectile Dysfunction
2
2011
25
0.180
Why?
Watchful Waiting
1
2020
18
0.180
Why?
Wine
2
2010
18
0.180
Why?
Carcinoma in Situ
2
2009
17
0.170
Why?
Survival Analysis
2
2017
225
0.170
Why?
Adolescent
5
2017
3714
0.170
Why?
Pilot Projects
1
2020
235
0.170
Why?
Carcinoma, Ductal, Breast
2
2009
57
0.170
Why?
India
7
2012
12
0.170
Why?
Kaplan-Meier Estimate
3
2015
127
0.160
Why?
Receptors, Estrogen
2
2016
56
0.160
Why?
Neoplasm Invasiveness
5
2024
83
0.160
Why?
Disease-Free Survival
2
2015
57
0.160
Why?
Vaccination
1
2023
664
0.160
Why?
Exercise
1
2022
478
0.160
Why?
Cell Cycle Proteins
2
2015
6
0.150
Why?
Apoptosis
2
2015
10
0.150
Why?
Leuprolide
1
2017
2
0.150
Why?
Goserelin
1
2017
2
0.150
Why?
Imidazolidines
1
2017
2
0.150
Why?
Flutamide
1
2017
3
0.150
Why?
Anilides
1
2017
3
0.150
Why?
Tosyl Compounds
1
2017
3
0.150
Why?
Nitriles
1
2017
7
0.150
Why?
Skin Diseases
3
2005
10
0.150
Why?
Hospitalization
1
2023
813
0.150
Why?
Antineoplastic Agents
2
2015
57
0.150
Why?
Diabetes Mellitus
2
2014
526
0.150
Why?
Clinical Laboratory Services
1
2016
1
0.150
Why?
Time Factors
6
2013
1114
0.140
Why?
Delivery of Health Care, Integrated
2
2021
552
0.140
Why?
Water Pollutants, Chemical
2
2007
4
0.140
Why?
Medical Records
2
2008
108
0.140
Why?
Administration, Oral
1
2016
81
0.140
Why?
Disease Progression
1
2017
255
0.140
Why?
Medroxyprogesterone Acetate
1
2015
16
0.140
Why?
Immunohistochemistry
4
2017
44
0.130
Why?
T-Lymphocyte Subsets
1
2015
4
0.130
Why?
Macrophages
1
2015
4
0.130
Why?
CD8-Positive T-Lymphocytes
1
2015
5
0.130
Why?
Forecasting
1
2016
77
0.130
Why?
Health Resources
1
2015
36
0.130
Why?
Nomograms
1
2015
13
0.130
Why?
Smoking
3
2022
465
0.130
Why?
Estrogen Replacement Therapy
1
2015
105
0.130
Why?
Apoptosis Regulatory Proteins
1
2015
4
0.130
Why?
Lymphocyte Activation
1
2015
7
0.130
Why?
SEER Program
4
2017
100
0.130
Why?
Mastectomy, Segmental
2
2012
23
0.130
Why?
European Continental Ancestry Group
3
2012
559
0.120
Why?
Prevalence
6
2014
892
0.120
Why?
Oncogene Proteins, Fusion
1
2013
3
0.110
Why?
Trans-Activators
1
2013
8
0.110
Why?
Health Behavior
2
2015
379
0.110
Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2011
68
0.110
Why?
Predictive Value of Tests
1
2014
350
0.110
Why?
Men's Health
2
2009
20
0.110
Why?
Epstein-Barr Virus Infections
1
2012
4
0.110
Why?
Life Style
2
2012
329
0.110
Why?
Dose-Response Relationship, Drug
3
2015
129
0.110
Why?
Lymphoma, AIDS-Related
1
2012
18
0.110
Why?
Fractures, Bone
1
2013
91
0.110
Why?
Gene Expression Regulation, Neoplastic
1
2012
55
0.100
Why?
Clinical Trials as Topic
1
2012
123
0.100
Why?
Acquired Immunodeficiency Syndrome
1
2012
66
0.100
Why?
Asian Continental Ancestry Group
1
2012
92
0.100
Why?
Health Care Surveys
1
2012
252
0.100
Why?
Mammary Glands, Human
1
2010
8
0.090
Why?
Health Status
2
2009
331
0.090
Why?
Medical Audit
1
2010
40
0.090
Why?
Prostatitis
1
2010
8
0.090
Why?
Massachusetts
1
2010
100
0.090
Why?
Health Status Disparities
1
2011
154
0.090
Why?
Family Characteristics
1
2009
53
0.090
Why?
Sexually Transmitted Diseases
1
2010
55
0.090
Why?
Educational Status
1
2009
205
0.080
Why?
Confounding Factors (Epidemiology)
1
2009
97
0.080
Why?
Enzyme Inhibitors
1
2008
3
0.080
Why?
Bias
1
2009
109
0.080
Why?
5-alpha Reductase Inhibitors
1
2008
7
0.080
Why?
Quality of Life
1
2012
509
0.080
Why?
Body Height
1
2008
59
0.080
Why?
Child
3
2022
2519
0.080
Why?
Population Surveillance
3
2016
270
0.080
Why?
Patient Education as Topic
1
2009
215
0.080
Why?
Risk Assessment
3
2020
1137
0.080
Why?
Residence Characteristics
1
2009
248
0.070
Why?
Body Weight
1
2008
216
0.070
Why?
Precancerous Conditions
1
2007
48
0.070
Why?
Fetal Development
1
2007
14
0.070
Why?
Cognition Disorders
1
2007
31
0.070
Why?
Age Factors
3
2015
945
0.070
Why?
Methionine
1
2005
6
0.070
Why?
Selenium
1
2005
4
0.070
Why?
Micronutrients
1
2005
9
0.070
Why?
beta Carotene
1
2005
18
0.070
Why?
Bronchiectasis
1
2005
2
0.070
Why?
Water
1
2005
2
0.070
Why?
Respiration Disorders
1
2005
4
0.070
Why?
Diabetes Mellitus, Type 2
1
2013
742
0.070
Why?
Automation
1
2005
24
0.060
Why?
Surveys and Questionnaires
4
2011
1346
0.060
Why?
Nutrition Disorders
1
2004
1
0.060
Why?
Skin Pigmentation
1
2004
6
0.060
Why?
Antibiotics, Antineoplastic
1
2024
8
0.060
Why?
Adjuvants, Immunologic
1
2024
15
0.060
Why?
Biopsy
2
2017
73
0.060
Why?
Proto-Oncogene Proteins c-bcl-6
2
2015
6
0.060
Why?
DNA-Binding Proteins
2
2015
30
0.060
Why?
Rural Population
1
2003
48
0.050
Why?
Leukocytes, Mononuclear
1
2022
9
0.050
Why?
Telomere
1
2022
19
0.050
Why?
Drug Administration Schedule
2
2015
97
0.050
Why?
Diet
1
2024
359
0.050
Why?
Tumor Burden
2
2013
20
0.050
Why?
Ovary
1
2020
4
0.050
Why?
BRCA2 Protein
1
2020
6
0.050
Why?
BRCA1 Protein
1
2020
6
0.050
Why?
Heterozygote
1
2020
29
0.050
Why?
Mutation
1
2020
129
0.050
Why?
Gene Expression Regulation
1
2017
23
0.040
Why?
ROC Curve
1
2017
79
0.040
Why?
In Situ Hybridization, Fluorescence
1
2016
15
0.040
Why?
CD4 Lymphocyte Count
1
2017
176
0.040
Why?
Biomarkers
1
2017
306
0.030
Why?
Antigens, Differentiation, Myelomonocytic
1
2015
3
0.030
Why?
Antigens, CD
1
2015
5
0.030
Why?
Severity of Illness Index
2
2009
454
0.030
Why?
Hysterectomy
1
2015
30
0.030
Why?
Forkhead Transcription Factors
1
2015
6
0.030
Why?
CD4-Positive T-Lymphocytes
1
2015
13
0.030
Why?
Reproducibility of Results
1
2016
394
0.030
Why?
Double-Blind Method
1
2015
160
0.030
Why?
Proliferating Cell Nuclear Antigen
1
2015
3
0.030
Why?
Interferon Regulatory Factors
1
2015
3
0.030
Why?
Protein Kinase C beta
1
2015
3
0.030
Why?
Hyaluronan Receptors
1
2015
4
0.030
Why?
Proto-Oncogene Proteins c-myc
1
2015
5
0.030
Why?
Immunoglobulin M
1
2015
8
0.030
Why?
Women's Health
1
2015
208
0.030
Why?
Postmenopause
1
2015
266
0.030
Why?
Orchiectomy
1
2014
5
0.030
Why?
Neoplasms, Hormone-Dependent
1
2014
9
0.030
Why?
Michigan
1
2014
26
0.030
Why?
Neoadjuvant Therapy
1
2014
14
0.030
Why?
Myocardial Infarction
1
2015
251
0.030
Why?
Mortality
1
2014
121
0.030
Why?
Transcriptional Regulator ERG
1
2013
3
0.030
Why?
Cause of Death
1
2014
181
0.030
Why?
Positive Regulatory Domain I-Binding Factor 1
1
2012
3
0.030
Why?
Ki-1 Antigen
1
2012
3
0.030
Why?
B7-1 Antigen
1
2012
3
0.030
Why?
LIM Domain Proteins
1
2012
3
0.030
Why?
In Situ Hybridization
1
2012
6
0.030
Why?
Repressor Proteins
1
2012
12
0.030
Why?
Adaptor Proteins, Signal Transducing
1
2012
15
0.030
Why?
Herpesvirus 4, Human
1
2012
7
0.030
Why?
NF-kappa B
1
2012
11
0.030
Why?
Proto-Oncogene Proteins
1
2012
36
0.030
Why?
Patient Selection
1
2012
194
0.020
Why?
Asian Americans
1
2011
184
0.020
Why?
Lymphatic Metastasis
1
2009
29
0.020
Why?
Acculturation
1
2009
22
0.020
Why?
Mastectomy
1
2009
36
0.020
Why?
Language
1
2009
52
0.020
Why?
Combined Modality Therapy
1
2009
147
0.020
Why?
Hispanic Americans
1
2011
431
0.020
Why?
Dutasteride
1
2008
1
0.020
Why?
Azasteroids
1
2008
1
0.020
Why?
Finasteride
1
2008
1
0.020
Why?
Data Interpretation, Statistical
1
2009
79
0.020
Why?
Adrenergic alpha-Antagonists
1
2008
9
0.020
Why?
African Continental Ancestry Group
1
2009
165
0.020
Why?
Recurrence
1
2009
186
0.020
Why?
Propensity Score
1
2009
90
0.020
Why?
Prostatic Hyperplasia
1
2008
24
0.020
Why?
Receptors, Progesterone
1
2008
51
0.020
Why?
African Americans
1
2011
485
0.020
Why?
Health Services Research
1
2009
271
0.020
Why?
Confidence Intervals
1
2008
249
0.020
Why?
Age Distribution
1
2008
257
0.020
Why?
Intelligence Tests
1
2007
4
0.020
Why?
Exanthema
1
2007
8
0.020
Why?
Epidemiological Monitoring
1
2007
26
0.020
Why?
Environmental Monitoring
1
2007
25
0.020
Why?
Statistics, Nonparametric
1
2005
50
0.020
Why?
Respiratory Function Tests
1
2005
20
0.020
Why?
Chi-Square Distribution
1
2005
160
0.020
Why?
Prenatal Exposure Delayed Effects
1
2007
144
0.020
Why?
Alcohol Drinking
1
2008
375
0.020
Why?
Nutritional Status
1
2004
30
0.020
Why?
Tomography, X-Ray Computed
1
2005
205
0.020
Why?
Health Surveys
1
2004
266
0.010
Why?
Child, Preschool
1
2007
1428
0.010
Why?
Pregnancy
1
2007
1484
0.010
Why?
Concepts (318)
Explore
_
Co-Authors (21)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_
-->

© 2024 Kaiser Permanente